Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma ‐ specific venous thrombosis prediction models

2020/05/08 by Gouri Dharmavaram, Shufen Cao, Suchitra Sundaram +12

paper · doi:10.1002/ajh.25837

Abstract

Abstract Venous thromboembolic events (VTE) are a frequent complication of lymphoma. We conducted a retrospective analysis to compare VTE risk in diffuse large B‐cell lymphoma (DLBCL) and follicular lymphoma (FL). Subjects were randomly assigned to training and validation sets to identify risk factors of VTE and evaluate risk model performance, including the Khorana score. A group of 790 patients were diagnosed from 2002 to 2014 (DLBCL = 542, FL = 248). Median follow‐ up was 49 months. We observed 106 VTE, with higher incidence in DLBCL (5‐year cumulative incidence = 16.3% vs 3.8% in FL patients). Five‐year OS for patients with VTE was 51.4% vs 73.1% in patients without VTE ( P

Related

• Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients
• Development and validation of a predictive model for chemotherapy-associated thrombosis
• Risk Factors of Venous Thromboembolic Disease in Cancer Patients Treated with Immune Checkpoint Inhibitor
• Association of Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio with the Risk of Thromboembolism and Mortality in Patients with Cancer
• Incidence of Venous Thromboembolism in the Year Before the Diagnosis of Cancer in 528 693 Adults